Chronic Obstructive Pulmonary Disease Market Intelligence: Epidemiology Analysis and Therapeutic Forecast to 2034

DelveInsight's comprehensive report on "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast 2034" delivers extensive understanding of Chronic Obstructive Pulmonary Disease, encompassing historical and projected epidemiology alongside therapeutic market dynamics in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore Chronic Obstructive Pulmonary Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Key Highlights from the Market Report

• On December 15, 2025- Sanofi commenced a Phase 2/Phase 3, 3-arm investigation to evaluate lunsekimig efficacy, safety, and tolerability via subcutaneous (SC) treatment compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.

• On December 12, 2025- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. announced a Phase II Clinical Investigation to Evaluate TQC2731 Injection Efficacy, Safety, and Pharmacokinetics in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

• The total number of diagnosed prevalent cases of COPD in the 7MM was approximately 31 million in 2024.

• In the US, cigarette smoking represents the primary COPD cause, with significantly elevated rates observed in both current and former smokers compared to those who never smoked. Additionally, individuals with higher family incomes tend to have lower COPD prevalence, indicating a correlation between socioeconomic status and disease risk.

• In comparison to the US, in EU4 and the UK, COPD continues demonstrating higher prevalence among men, largely reflecting historical patterns of elevated smoking rates and occupational exposures in male populations. Although the gender gap has narrowed over time with rising diagnoses in women, men still represent a larger share of the COPD burden.

• In EU4 and the UK, COPD cases were highest in Germany in 2024, whereas the minimum case numbers were in the UK in 2024.

• The US accounted for the highest GOLD 2 cases (~8.2 million), which were followed by GOLD 3 (~4.3 million) cases, compared to other countries in the 7MM.

• In 2024, chronic bronchitis accounted for the highest share of COPD cases in EU4 and the UK, comprising approximately 6.42 million cases.

• In Japan, there is a significant gap between estimated COPD patient numbers and those receiving treatment, indicating widespread underdiagnosis; this highlights the high unmet need to enhance early detection and management efforts. Japan observed the maximum case numbers from the 65-74 years age group (~283,000) in 2024.

• Key pharmaceutical developers include AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others.

• Notable therapies comprise BFF MDI 320/9.6 μg, QVA149, NVA237, Depemokimab, PF-00610355, Astegolimab, Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, and others.

Strategize your business goals by understanding market dynamics @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Understanding Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) represents a progressive and long-term respiratory disorder characterized by persistent airflow limitation that is not fully reversible and worsens over time, primarily due to chronic inflammation of the airways and lung tissue. It encompasses conditions such as chronic bronchitis, marked by excessive mucus production and cough, and emphysema, which involves alveolar destruction leading to reduced gas exchange.

Epidemiological Segmentation in the 7MM

• Total Diagnosed Prevalent Cases

• Subtype-specific Diagnosed Prevalent Cases

• Gender-specific Diagnosed Prevalent Cases

• Age-specific Diagnosed Prevalent Cases

• Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation

• Treatment eligible pool

Visit for more about Chronic Obstructive Pulmonary Disease Prevalence @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Marketed Chronic Obstructive Pulmonary Disease Therapeutics

NUCALA: GSK Pharmaceuticals NUCALA (mepolizumab) represents a fixed-dose biologic therapy approved for subcutaneous injection to treat severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES), and recently, eosinophilic phenotype COPD. NUCALA is available as prefilled syringes, autoinjectors, and powder for injection, designed for easy and flexible use by healthcare providers or patients after training. The medication requires refrigeration and is intended for single-patient use. This delivery system supports convenient, at-home treatment of eosinophilic respiratory diseases. In May 2025, GSK announced that the US FDA approved NUCALA for use in adults with COPD. The approval was based on data from the METREX and METREO Phase III trials, which showed statistically significant reduction in moderate and severe exacerbations in patients with elevated eosinophil counts who were already on maximum inhaled therapies. According to GSK's 2025 Q1 presentation, the filing for NUCALA in Europe is planned for 2026.

DUPIXENT: Regeneron Pharmaceuticals/Sanofi DUPIXENT (dupilumab), developed by Regeneron Pharmaceuticals/Sanofi, is primarily developed for treating adult patients with uncontrolled COPD, which is administered SC. DUPIXENT is the first biologic to be approved in Europe, changing the entire market pursuit from now on. Recently, DUPIXENT has achieved a significant milestone with its approval as the first-in-world treatment for adults with uncontrolled COPD characterized by elevated blood eosinophils. This decision follows two pivotal Phase III studies, which demonstrated that DUPIXENT effectively reduced exacerbations, enhanced lung function, and improved health-related quality of life. In September 2024, the US FDA approved DUPIXENT (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. DUPIXENT is the first biologic medicine approved in the US to treat these patients. Sanofi and Regeneron have jointly developed DUPIXENT under a global collaboration agreement. Dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by Type 2 inflammation. Apart from its existing approved uses, Sanofi and Regeneron are investigating dupilumab in Phase III trials for various conditions influenced by Type 2 inflammation or allergic reactions.

OHTUVAYRE: Verona Pharma OHTUVAYRE represents a first-in-class selective dual inhibitor of the enzymes PDE3 and PDE4 that combines bronchodilator and nonsteroidal anti-inflammatory effects in one molecule. OHTUVAYRE met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD. Ensifentrine has potential applications for development in noncystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases.

Emerging Chronic Obstructive Pulmonary Disease Therapeutics

Depemokimab: GSK Depemokimab represents the first ultra-long-acting biologic to be evaluated in a Phase III trial with binding affinity and high potency for IL-5, enabling 6-month dosing intervals for patients. IL-5 is known to be a key cytokine (protein) in Type 2 inflammation. As per GSK's Q1 presentation, the Phase III clinical trial of depemokimab is expected to start in H2 2025.

Itepekimab: Regeneron Pharmaceuticals/Sanofi Itepekimab represents a fully human mAb that binds to and inhibits IL-33, an initiator and amplifier of broad inflammation in COPD. IL-33 is thought to be involved in different types of inflammation and is particularly elevated in the lungs of former smokers. Sanofi and Regeneron are jointly developing Itepekimab under a global collaboration agreement.

TEZSPIRE (tezepelumab): AstraZeneca/Amgen TEZSPIRE represents a first-in-class human mAb that inhibits TSLP action, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic, and other types of epithelial-driven inflammation associated with severe asthma and other inflammatory diseases.

For more information, visit Chronic Obstructive Pulmonary Disease Medication and Companies @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Market Forecast Outlook

The Chronic Obstructive Pulmonary Disease market is expected to grow steadily over the coming years, driven by rising disease prevalence, aging populations, and increased awareness and diagnosis. While traditional inhaled therapies like LABAs, LAMAs, and ICS remain the mainstay, the landscape is evolving with the introduction of novel agents, including biologics and dual-action molecules like PDE inhibitors.

Featured Companies

AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others.

Report Scope

• Geographic Coverage: 7MM

• Study Period: 2020-2034

• Featured Companies: AstraZeneca/Circassia Pharmaceuticals Inc., GlaxoSmithKline/Theravance, Inc/Innoviva, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Sanofi/Regeneron Pharmaceuticals, United Therapeutics, Verona Pharma PLC, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex Pharmaceuticals Incorporated, Pulmotect Inc., Genentech, Mereo BioPharma, Biomarck Pharmaceuticals and others

• Pipeline Therapies: BFF MDI 320/9.6 μg, QVA149, NVA237, Depemokimab, PF-00610355, Astegolimab, Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, and others

• Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies

• Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Additional Coverage: Chronic Obstructive Pulmonary Disease Unmet Needs, KOL's views, Analyst's views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

Do you know the treatment paradigms for different countries? Download our Chronic Obstructive Pulmonary Disease Treatment Market @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

1. Key Insights

2. Chronic Obstructive Pulmonary Disease Market Report Introduction

3. Executive Summary

4. Chronic Obstructive Pulmonary Disease Market Overview at a Glance

5. Key Chronic Obstructive Pulmonary Disease Events

6. Chronic Obstructive Pulmonary Disease Epidemiology and Market Methodology

7. Chronic Obstructive Pulmonary Disease Background and Overview

8. Chronic Obstructive Pulmonary Disease Treatment and Management

9. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population

10. Chronic Obstructive Pulmonary Disease Patient Journey

11. Chronic Obstructive Pulmonary Disease Marketed Drugs

12. Chronic Obstructive Pulmonary Disease Discontinued Product

13. Chronic Obstructive Pulmonary Disease Emerging Drugs

14. Chronic Obstructive Pulmonary Disease: Seven Major Market Analysis

15. Chronic Obstructive Pulmonary Disease Unmet Needs

16. Chronic Obstructive Pulmonary Disease SWOT Analysis

17. Chronic Obstructive Pulmonary Disease KOL Views

18. Chronic Obstructive Pulmonary Disease Market Access and Reimbursement

19. Appendix

20. Delveinsight Capabilities

21. Disclaimer

22. About Delveinsight

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us

Kanishk

kkumar@delveinsight.com